Market Overview

Research and Markets: Ischemia Reperfusion Injury - Pipeline Review, H2 2012 Features Players such as BioLineRx, Ltd. and Omeros Corporation


Research and Markets ( has announced the addition of Global Markets Direct's new report "Ischemia Reperfusion Injury - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Ischemia Reperfusion Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Ischemia Reperfusion Injury.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Ischemia Reperfusion Injury pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Mentioned:

- Pharming Group N.V.

- BioLineRx, Ltd.

- Trophos SA

- Alligator Bioscience AB

- Opsona Therapeutics Ltd.

- Omeros Corporation

- Bolder Biotechnology, Inc.

- Ischemix

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

View Comments and Join the Discussion!